Click on the issue number to the left of the topics to jump to the page with that issue.
|
Issue |
Topic |
|
A new tool for DNA editing |
|
|
Pharma makes most of its money from “old” drugs |
|
|
Bacteria in the brain |
|
|
Brain injury an autoimmune disease? |
|
|
First new mechanism TB drug in 40 years |
|
|
Who spends the most on R&D? |
|
|
More VCs going without syndicates |
|
|
Her2 drives breast cancer stem cells in the absence of Her2 amplification |
|
|
Off-label use in oncology |
|
|
Deal numbers for 2012 – not good |
|
|
VC investments down |
|
|
M&A numbers down, but sales multiple up |
|
|
Licensing deals down, especially Phase 1 & 3 |
|
|
Modeling VEGF and BDNF forming blood vessels |
|
|
Rethink our failures – more orphans coming? |
|
|
Male cells inside female brains - Microchimerisms |
|
|
My top trends of 2012 |
|
|
Generics and biosimilars – important, hard and sometimes dangerous |
|
|
Productivity challenges |
|
|
A mixed economy for the drug industry |
|
|
Pressure on pricing and value |
|
|
New success with high risk approaches |
|
|
Tech is changing health care |
|
|
Targets for platform technologies |
|
|
Top licensing and JV deal makers |
|
|
VC investments |
|
|
Challenges of partnering early innovation |
|
|
Human cells respond to bacterial quorum sensing |
|
|
Pricing problems all over the place |
|
|
Help your deals lawyer |
|
|
When is bioequivalence not enough? |
|
|
IPOs, Exits in US and China |
|
|
Pharmaceutical Compounding and Risks |
|
|
Deals: University Collaborations |
|
|
R&D, earnings and jobs UP |
|
|
Help your deals lawyer |
|
|
When is bioequivalence not enough? |
|
|
IPOs, Exits in US and China |
|
|
Biggest risk for pharma - demonstrating value |
|
|
DEAL: Onconova and Baxter sign European deal for Phase III cancer drug |
|
|
Corporate VC investments back up for Q2 |
|
|
Ex-Amgener starts an incubator, Ventura BioCenter, and a Fermentation Seminar |
|
|
DEAL: Atlas funds put to work toward prenegotiated deal with The Medicines Company |
|
|
Biggest risk for pharma - demonstrating value |
|
|
DEAL: Onconova and Baxter sign European deal for Phase III cancer drug |
|
|
Corporate VC investments back up for Q2 |
|
|
Ex-Amgener starts an incubator, Ventura BioCenter, and a Fermentation Seminar |
|
|
Genes can be patented, says Appeals Court |
|
|
Diarrhea drug is 1st oral med to get extra from Medicare as new technology |
|
|
What we did not know! |
|
|
Part 1. Protein takes 2 very different structures and 2 jobs |
|
|
Part 2. The brain has a newly discovered waste disposal |
|
|
DEAL: Novartis rewards U Penn's high-risk translational work |
|
|
DEAL: Is RNA hot? RNA deal of Regulus and AstraZeneca |
|
|
Product licensing deals a mixed picture? |
|
|
Amyloid trial in Alzheimer's fails - just intervention too late? |
|
|
Crowd-funding for biotech |
|
|
VC funding and firms down, M&A up with big VC exits |
|
|
Outcomes Research rushing ahead, before the rules are set |
|
|
T cells move like sharks and other predators |
|
|
FDA reviews faster than EMEA or Canada, but more cycles |
|
|
With big Phase III expenses, should we have more conditional approvals |
|
|
Old targets, versus the challenge of pitching the new |
|
|
Clinical Development Success Rates |
|
|
Funding Trends: VCs, IPOs, M&A |
|
|
Hubbub for disease definitions for psychosis, autism |
|
|
A few miracle patients get ALK diagnostic adopted, but at what cost effectiveness? |
|
|
16% of cancers from infection- Now where did that number come from? |
|
|
The Skeptical VC or Partner |
|
|
The Black Queen Hypothesis- Eliminating Genes with Outsourcing |
|
|
Getting Fired from your own Startup |
|
|
Cancer cell line encyclopedia of genetics and drug response |
|
|
Bruce Booth on business models and critical success factors |
|
|
Are Genes Patentable? Myriad Case Heads back to Supreme Court after Prometheus Decision |
|
|
Big Trend of 2011, VC funds and Series A UP, IPOs raise less money |
|
|
Austerity means continued government pressure on drug prices |
|
|
AstraZeneca sues FDA over Seroquel Generic Labels |
|
|
Oncology Deal Making Panels say "Good opportunities scarce and valuable" |
|
|
R&D Costs and Dropping Productivity |
|
|
Who owns what? Agios deal triggers a lawsuit |
|
|
www.e-Prognosis.org - a web tool to predict likelihood of death |
|
|
Science behind the benefits of exercise and massage |
|
|
Tau versus Amyloid in Alzheimer's Disease |
|
|
Visions of a grand biotech future? |
|
|
New Teva CEO is former deal maker for BMS-- What will change? |
|
|
A glass half-full and a need for optimism |
|
|
Big pharma R&D productivity falls; Roche CEO believes "me too's" will be squeezed |
|
|
Life Science Venture Capital down 21% for 3rd quarter |
|
|
Biotech building boom in Boston/Cambridge, Bay Area |
|
|
Clearing the body of senescent cells could slow aging |
|
|
Small IPOs decline from 80% to less than 20% of all IPOs |
|
|
Avastin fails on appeal to keep breast cancer approval in US; Roche will do a trial with VEGF-A as biomarker |
|
|
New support for startups in House bills? |
|
|
Stanford incubator pays its entrepreneurs; U Michigan invests in startups. |
|
|
Personalized Medicine TV |
|
|
Trends transforming the business of oncology |
|
|
Quantum mechanics in biology? |
|
|
Pricing challenges for incremental innovators |
|
|
A software algorithm to score VC investment requests at Right Side Capital Management |
|
|
Green fluorescent tags cancer cells for excision |
|
|
Signaling pathways have low information, requiring multiple cells to chatter |
|
|
FDA conservatism decreases VC funding, especially in areas with high safety hurdles |
|
|
More projects at Phase III a cause for optimism on industry productivity |
|
|
Patent reform creates first-to-file system in the US |
|
|
Antibodies and payloads |
|
|
Big company to get funding for development from small company |
|
|
Gamers solve tough protein folding problem |
|
|
Richard Hsu’s blog and my “10 Considerations in a Life Science License” |
|
|
Great ideas for spurring biotech |
|
|
House members try to shorten 12 years of biologics exclusivity |
|
|
Tufts: CNS drugs are tough to develop |
|
|
M&A up in the first half of 2011 - returns to VCs up too |
|
|
What makes a great partnering meeting? |
|
|
Myriad gene patent upheld in appeals court |
|
|
Big buzz on results with genetically modified T cells, but.... |
|
|
Biotechs raise more money; VCs cautiously increase seed stage |
|
|
NSCLC screening- reduced mortality by 20% but 95% false positives |
|
|
Comparing Lilly and Pfizer paths to growth |
|
|
Investors getting returns in licensing deals |
|
|
Drama in deal making for a lung cancer diagnostic |
|
|
ASCO take-aways: longer survival and longer treatment |
|
|
Supreme Court says Bayh-Dole does not mean inventions are automatically owned by the university |
|
|
Real benefits from NIH (and biotech and pharma) |
|
|
Check out my post on "leave pieces" |